Walleye Capital
BIO icon

Walleye Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Walleye Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,400
Closed -$1.2M – 5301
2024
Q2 		$1.2M Buy
4,400
+4,100
+1,367% +$1.19M ﹤0.01% 2644
2024
Q1 		$104K Sell
300
-1,700
-85% -$559K ﹤0.01% 4376
2023
Q4 		$646K Buy
+2,000
New +$627K ﹤0.01% 2737
2020
Q1 		– Sell
-400
Closed -$148K – 958
2019
Q4 		$148K Sell
400
-1,100
-73% -$388K 0.01% 1243
2019
Q3 		$499K Sell
1,500
-6,500
-81% -$2.12M 0.03% 755
2019
Q2 		$2.5M Buy
+8,000
New +$2.4M 0.27% 64

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Walleye Capital's BIO Position: Q3 2024 in Review

Walleye Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 1,500 shares — an estimated $410K sold.

Walleye Capital first reported a position in BIO in Q2 2019 and held it in 10 quarters. The position peaked at $4.87M in Q1 2022. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

  • Walleye Capital reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 1,500 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $410K.
  • Walleye Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and held it in 10 quarters.
  • Walleye Capital's Bio-Rad Laboratories Class A position peaked at $4.87M in Q1 2022.
  • 438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.